Ranibizumab in diabetic macular edema
By 2050 the prevalence of diabetes will more than triple globally,dramatically increasing the societal and financial burden of this disease worldwide.As a consequence of this growth,it is anticipated that there will be a concurrent rise in the numbers of patients with diabetic macular edema(DME),alr...
Gespeichert in:
| Veröffentlicht in: | World journal of diabetes 2013-12, Vol.4 (6), p.310-318 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 318 |
|---|---|
| container_issue | 6 |
| container_start_page | 310 |
| container_title | World journal of diabetes |
| container_volume | 4 |
| creator | Krispel, Claudia Rodrigues, Murilo Xin, Xiaoban Sodhi, Akrit |
| description | By 2050 the prevalence of diabetes will more than triple globally,dramatically increasing the societal and financial burden of this disease worldwide.As a consequence of this growth,it is anticipated that there will be a concurrent rise in the numbers of patients with diabetic macular edema(DME),already among the most common causes of severe vision loss worldwide.Recent available therapies for DME target the secreted cytokine,vascular endothelial growth factor(VEGF).This review focuses on the treatment of DME using the first humanized monoclonal antibody targeting VEGF that has been Food and Drug Administrationapproved for the use in the eye,ranibizumab(Lucentis). |
| doi_str_mv | 10.4239/wjd.v4.i6.310 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3874491</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>1003029645</cqvip_id><sourcerecordid>1540109182</sourcerecordid><originalsourceid>FETCH-LOGICAL-c345t-7d92e805fda8a452ad2cca6534ba0e769c7c630af9d0e7ad9662aac741524ddb3</originalsourceid><addsrcrecordid>eNpVkMtLw0AQhxdRbKk9epWACF4S953sRZDiCwRB9LxMdjftljzabFLRv95Ia6lzmVn245vhh9A5wQmnTN18Lm2y4YmXCSP4CI2J4lmsmMiOD-YRmoawxENxISVTp2hEOUuVonSMrt6g9rn_7ivII19H1kPuOm-iCkxfQhs56yo4QycFlMFNd32CPh7u32dP8cvr4_Ps7iU2jIsuTq2iLsOisJABFxQsNQakYDwH7FKpTGokw1AoOzzBKikpgEk5EZRbm7MJut16V31eOWtc3bVQ6lXrK2i_dANe__-p_ULPm41mWcq5IoPgeidom3XvQqcrH4wrS6hd0wdNBMcEK5LRAY23qGmbEFpX7NcQrH_T1UO6esO1l3pId-AvDm_b039ZDsDlTrho6vna1_MDI2aYKskF-wHpWYJj</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1540109182</pqid></control><display><type>article</type><title>Ranibizumab in diabetic macular edema</title><source>Baishideng "World Journal of" online journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Krispel, Claudia ; Rodrigues, Murilo ; Xin, Xiaoban ; Sodhi, Akrit</creator><creatorcontrib>Krispel, Claudia ; Rodrigues, Murilo ; Xin, Xiaoban ; Sodhi, Akrit</creatorcontrib><description>By 2050 the prevalence of diabetes will more than triple globally,dramatically increasing the societal and financial burden of this disease worldwide.As a consequence of this growth,it is anticipated that there will be a concurrent rise in the numbers of patients with diabetic macular edema(DME),already among the most common causes of severe vision loss worldwide.Recent available therapies for DME target the secreted cytokine,vascular endothelial growth factor(VEGF).This review focuses on the treatment of DME using the first humanized monoclonal antibody targeting VEGF that has been Food and Drug Administrationapproved for the use in the eye,ranibizumab(Lucentis).</description><identifier>ISSN: 1948-9358</identifier><identifier>EISSN: 1948-9358</identifier><identifier>DOI: 10.4239/wjd.v4.i6.310</identifier><identifier>PMID: 24379922</identifier><language>eng</language><publisher>United States: Baishideng Publishing Group Co., Limited</publisher><subject>Avastin ; Bevacizumab ; Diabetes ; edema ; endothelial ; factor ; growth ; injection ; Intravitreal ; Lucentis ; Macular ; Ranibizumab ; Topic Highlight ; Vascular</subject><ispartof>World journal of diabetes, 2013-12, Vol.4 (6), p.310-318</ispartof><rights>2013 Baishideng Publishing Group Co., Limited. All rights reserved. 2013</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c345t-7d92e805fda8a452ad2cca6534ba0e769c7c630af9d0e7ad9662aac741524ddb3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/71418X/71418X.jpg</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874491/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3874491/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24379922$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Krispel, Claudia</creatorcontrib><creatorcontrib>Rodrigues, Murilo</creatorcontrib><creatorcontrib>Xin, Xiaoban</creatorcontrib><creatorcontrib>Sodhi, Akrit</creatorcontrib><title>Ranibizumab in diabetic macular edema</title><title>World journal of diabetes</title><addtitle>World Journal of Diabetes</addtitle><description>By 2050 the prevalence of diabetes will more than triple globally,dramatically increasing the societal and financial burden of this disease worldwide.As a consequence of this growth,it is anticipated that there will be a concurrent rise in the numbers of patients with diabetic macular edema(DME),already among the most common causes of severe vision loss worldwide.Recent available therapies for DME target the secreted cytokine,vascular endothelial growth factor(VEGF).This review focuses on the treatment of DME using the first humanized monoclonal antibody targeting VEGF that has been Food and Drug Administrationapproved for the use in the eye,ranibizumab(Lucentis).</description><subject>Avastin</subject><subject>Bevacizumab</subject><subject>Diabetes</subject><subject>edema</subject><subject>endothelial</subject><subject>factor</subject><subject>growth</subject><subject>injection</subject><subject>Intravitreal</subject><subject>Lucentis</subject><subject>Macular</subject><subject>Ranibizumab</subject><subject>Topic Highlight</subject><subject>Vascular</subject><issn>1948-9358</issn><issn>1948-9358</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNpVkMtLw0AQhxdRbKk9epWACF4S953sRZDiCwRB9LxMdjftljzabFLRv95Ia6lzmVn245vhh9A5wQmnTN18Lm2y4YmXCSP4CI2J4lmsmMiOD-YRmoawxENxISVTp2hEOUuVonSMrt6g9rn_7ivII19H1kPuOm-iCkxfQhs56yo4QycFlMFNd32CPh7u32dP8cvr4_Ps7iU2jIsuTq2iLsOisJABFxQsNQakYDwH7FKpTGokw1AoOzzBKikpgEk5EZRbm7MJut16V31eOWtc3bVQ6lXrK2i_dANe__-p_ULPm41mWcq5IoPgeidom3XvQqcrH4wrS6hd0wdNBMcEK5LRAY23qGmbEFpX7NcQrH_T1UO6esO1l3pId-AvDm_b039ZDsDlTrho6vna1_MDI2aYKskF-wHpWYJj</recordid><startdate>20131215</startdate><enddate>20131215</enddate><creator>Krispel, Claudia</creator><creator>Rodrigues, Murilo</creator><creator>Xin, Xiaoban</creator><creator>Sodhi, Akrit</creator><general>Baishideng Publishing Group Co., Limited</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W91</scope><scope>~WA</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20131215</creationdate><title>Ranibizumab in diabetic macular edema</title><author>Krispel, Claudia ; Rodrigues, Murilo ; Xin, Xiaoban ; Sodhi, Akrit</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c345t-7d92e805fda8a452ad2cca6534ba0e769c7c630af9d0e7ad9662aac741524ddb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Avastin</topic><topic>Bevacizumab</topic><topic>Diabetes</topic><topic>edema</topic><topic>endothelial</topic><topic>factor</topic><topic>growth</topic><topic>injection</topic><topic>Intravitreal</topic><topic>Lucentis</topic><topic>Macular</topic><topic>Ranibizumab</topic><topic>Topic Highlight</topic><topic>Vascular</topic><toplevel>online_resources</toplevel><creatorcontrib>Krispel, Claudia</creatorcontrib><creatorcontrib>Rodrigues, Murilo</creatorcontrib><creatorcontrib>Xin, Xiaoban</creatorcontrib><creatorcontrib>Sodhi, Akrit</creatorcontrib><collection>中文科技期刊数据库</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库-医药卫生</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of diabetes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Krispel, Claudia</au><au>Rodrigues, Murilo</au><au>Xin, Xiaoban</au><au>Sodhi, Akrit</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ranibizumab in diabetic macular edema</atitle><jtitle>World journal of diabetes</jtitle><addtitle>World Journal of Diabetes</addtitle><date>2013-12-15</date><risdate>2013</risdate><volume>4</volume><issue>6</issue><spage>310</spage><epage>318</epage><pages>310-318</pages><issn>1948-9358</issn><eissn>1948-9358</eissn><abstract>By 2050 the prevalence of diabetes will more than triple globally,dramatically increasing the societal and financial burden of this disease worldwide.As a consequence of this growth,it is anticipated that there will be a concurrent rise in the numbers of patients with diabetic macular edema(DME),already among the most common causes of severe vision loss worldwide.Recent available therapies for DME target the secreted cytokine,vascular endothelial growth factor(VEGF).This review focuses on the treatment of DME using the first humanized monoclonal antibody targeting VEGF that has been Food and Drug Administrationapproved for the use in the eye,ranibizumab(Lucentis).</abstract><cop>United States</cop><pub>Baishideng Publishing Group Co., Limited</pub><pmid>24379922</pmid><doi>10.4239/wjd.v4.i6.310</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1948-9358 |
| ispartof | World journal of diabetes, 2013-12, Vol.4 (6), p.310-318 |
| issn | 1948-9358 1948-9358 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3874491 |
| source | Baishideng "World Journal of" online journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Avastin Bevacizumab Diabetes edema endothelial factor growth injection Intravitreal Lucentis Macular Ranibizumab Topic Highlight Vascular |
| title | Ranibizumab in diabetic macular edema |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T21%3A18%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ranibizumab%20in%20diabetic%20macular%20edema&rft.jtitle=World%20journal%20of%20diabetes&rft.au=Krispel,%20Claudia&rft.date=2013-12-15&rft.volume=4&rft.issue=6&rft.spage=310&rft.epage=318&rft.pages=310-318&rft.issn=1948-9358&rft.eissn=1948-9358&rft_id=info:doi/10.4239/wjd.v4.i6.310&rft_dat=%3Cproquest_pubme%3E1540109182%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1540109182&rft_id=info:pmid/24379922&rft_cqvip_id=1003029645&rfr_iscdi=true |